INGRAALYS is a research-driven start-up advancing the next generation of anti-aging skincare. We provide cosmetic companies with cutting-edge biological tools to evaluate the efficacy and safety of their products—faster, deeper, and with scientific rigor.
Our core strengths lie in:
• Human skin cell culture (keratinocytes, fibroblasts, melanocytes)
• Ex vivo skin explant testing
• Cellular reprogramming models targeting aged/senescent cells
• RNA sequencing and gene expression profiling
• Histological and immunofluorescence analysis
Founded in 2017 by Dr. Claude Chauchard, INGRAALYS is headquartered within the CYBORG incubator at the IRMB (Institute for Regenerative Medicine and Biotherapies), where our scientific partner Prof. Jean-Marc Lemaitre leads a world-renowned research team on genome and stem cell plasticity in aging.
This partnership is rooted in nearly two decades of INSERM-backed academic research (AVENIR Program, IRMB/U1183) on reversing cellular aging through reprogramming strategies. These findings now power our testing platforms and innovation pipeline.
For collaboration or inquiries, contact us at: ingraalys1@orange.fr
Company Details
- Employees
- 4
- Founded
- -
- Address
- Montpellier, Fr
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Dermocosmetic Innovation, Anti-Aging Research, Skin Cell Culture, Regenerative Medicine, Cosmetic Product Testing.
- HQ
- Montpellier
Ingraalys Questions
Ingraalys's LinkedIn profile is https://fr.linkedin.com/company/ingraalys
Ingraalys has
4 employees.
View email and phone details for 4
employees at Ingraalys.
Ingraalys's industry is
Biotechnology Research
Ingraalys's top competitors are
Atoxigen,
Girls Into Vc At Berkeley,
Organips,
Critical,
Greenphage,
Medxcell Sa,
Uc Berkeley Innovation & Entrepreneurship,
Healthaging Biosciences,
Connecther®,
Hello Sunshine.
Ingraalys's categories are Biotechnology Research
Ingraalys's founding year is 2017
